NCT00999037

FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: University of California, Los Angeles · Academic / Other
• Sex: All
• Age: 6 Years – 21 Years
• Healthy volunteers: Not accepted

Summary

FGF-23 is a newly described protein that is an important regulator of phosphorus in the body. This protein increases in people with kidney disease and people who need dialysis have very high levels of FGF-23 in the blood. However, although some studies have indicated that FGF-23 levels go up with increased intake of phosphorus, no one knows if FGF-23 levels can be lowered in patients with kidney disease by preventing them from absorbing phosphorus from food. This study is designed to see what happens to levels of FGF-23 in the blood when patients with chronic kidney disease take medications to prevent phosphorus absorption. Since high levels of FGF-23 have been linked with increased rates of death in patients with advanced kidney disease, controlling the levels may, in the future, be a way to decrease heart disease in patients with kidney disease.

Conditions

• Secondary Hyperparathyroidism

Interventions

Type	Name	Description
DRUG	Sevelamer Carbonate	Daily renvela (800 mg tid with meals) x 12 weeks
OTHER	Placebo	1 inert tablet tid x 12 weeks

Timeline

• Start date: 2009-10-01
• Primary completion: 2015-06-01
• Completion: 2015-06-01
• First posted: 2009-10-21
• Last updated: 2023-05-31
• Results posted: 2017-03-31

Locations

1 site across 1 country: United States